1 Medicine Institute and.
2 Respiratory Institute, Cleveland Clinic, Cleveland, Ohio.
Ann Am Thorac Soc. 2017 Sep;14(9):1450-1456. doi: 10.1513/AnnalsATS.201612-1023OC.
RATIONALE: The U.S. Preventive Services Task Force recommends lung cancer screening with low-dose chest computed tomographic scans (LDCT) for a well-defined high-risk population. Data on the frequency and impact of incidental findings (IFs) based on LDCT scans performed within a centralized lung cancer screening program have not been reported. OBJECTIVES: Researchers in previous studies have reported IFs in the setting of clinical trials. We present our findings in a real clinical setting where the decision to manage these findings may depend on factors that are not captured in a research trial such as disclosing IFs, patient preferences, severity of comorbidities, and physician expertise. METHODS: We conducted a retrospective chart review of participants in the Cleveland Clinic Lung Cancer Screening Program from April 1, 2015, to February 17, 2016. Lung Imaging Reporting and Data System categories and all reported findings were extracted from the structured radiology report. Downstream investigations that occurred as a result of the imaging findings were recorded. Medicare reimbursement rates were documented for all screening-related testing and treatment. RESULTS: A total of 320 LDCT-screened patients' records were reviewed. The most commonly reported IFs were pulmonary (69.6%), cardiovascular (67.5%), and gastrointestinal (25.9%). Fifteen percent of the scans had an IF that resulted in further evaluation. The majority of patients who underwent further testing had cardiovascular findings (10.3%); less frequently, they had thyroid or adrenal nodules (2.1%), hepatic lesions (0.9%), renal masses (0.6%), or pulmonary disease (0.6%). The most frequently ordered investigations were echocardiography (n = 9), cardiac stress test (n = 9), and CT angiography (n = 6). Reimbursement for the screening process, evaluation, and treatment of screening-detected findings averaged $817 per screened patient. CONCLUSIONS: Clinically significant IFs on LDCT scans for lung cancer screening are common, and their potential impact should be included in the shared decision-making process. Screening program staff should develop a standard approach for the evaluation of these findings and consider the financial impact when seeking infrastructure support for screening program implementation.
背景:美国预防服务工作组建议对明确的高危人群进行低剂量胸部 CT 扫描(LDCT)肺癌筛查。尚未报道基于集中式肺癌筛查计划进行的 LDCT 扫描偶然发现(IF)的频率和影响的数据。
目的:以前的研究人员在临床试验环境中报告了 IF。我们在实际临床环境中报告了我们的发现,在这种环境中,管理这些发现的决定可能取决于临床试验中未捕获的因素,例如披露 IF、患者偏好、合并症的严重程度和医生的专业知识。
方法:我们对 2015 年 4 月 1 日至 2016 年 2 月 17 日期间参加克利夫兰诊所肺癌筛查计划的参与者进行了回顾性图表审查。从结构化放射学报告中提取了 Lung Imaging Reporting and Data System 类别和所有报告的发现。记录了由于影像学发现而进行的下游调查。记录了所有与筛查相关的检测和治疗的医疗保险报销率。
结果:共审查了 320 例 LDCT 筛查患者的记录。报告的最常见的 IF 是肺部(69.6%)、心血管(67.5%)和胃肠道(25.9%)。15%的扫描有导致进一步评估的 IF。大多数接受进一步检查的患者有心血管发现(10.3%);较少见的是甲状腺或肾上腺结节(2.1%)、肝病变(0.9%)、肾肿块(0.6%)或肺部疾病(0.6%)。最常进行的检查是超声心动图(n=9)、心脏应激试验(n=9)和 CT 血管造影(n=6)。筛查过程、评估和筛查发现的治疗的报销平均为每位筛查患者 817 美元。
结论:在 LDCT 扫描肺癌筛查中,临床上有意义的 IF 很常见,应将其潜在影响纳入共同决策过程。筛查计划工作人员应制定评估这些发现的标准方法,并在为筛查计划实施寻求基础设施支持时考虑财务影响。
Can Assoc Radiol J. 2010-4-10
Sci Rep. 2025-8-18
Eur Radiol. 2025-4-15
Am J Respir Crit Care Med. 2025-3
Ulus Travma Acil Cerrahi Derg. 2024-8
Eur Radiol. 2025-1
Am J Respir Crit Care Med. 2024-8-1